Nalaganje...
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to EGFR tyrosine kinase inhibitors (TKIs). First-generation reversible EGFR TKIs, gefitinib and erlotinib have been proven...
Shranjeno v:
| izdano v: | Ther Adv Respir Dis |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204616/ https://ncbi.nlm.nih.gov/pubmed/30355049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618808659 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|